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Review Article
Review of Protocols Used in Ultrasound Thrombolysis
Nicos Papadopoulos, PhD,* Panayiotis A. Kyriacou, PhD,* and
Christakis Damianou, PhD†
Introduction
One of the early investigators who used ultrasound (US)
energy to accelerate the fibrinolytic activity of thrombo-
lytic drugs in vitro was Lauer.1 Later, more in vitro studies
have shown that US applications improved thromboly-
sis induced by thrombolytic agents (sonothrombolysis).
The main goal in these in vitro studies was to deduce
the optimum ultrasonic parameters to enhance
sonothrombolysis (mostly frequency and intensity).2 Another
major goal was to test the best thrombolytic drug that
enhances sonothrombolysis.3,4 The knowledge on
sonothrombolysis gained in the in vitro studies was trans-
lated at a preclinical level by performing experiments in
animals. Because in the in vitro experiments no side effects
can be extracted, experimentation with animals was im-
perative. Still the main goal in the animal experiments
was to extract the optimum ultrasonic parameters that
maximize clot removal.5 Additionally, different clot animal
models were used which could test the various derived
ultrasonic protocols.6,7 Progressively, US bubbles were em-
ployed which can possibly enhance the efficacy of
sonothrombolysis.5 When sufficient data were collected
this research was translated into clinical trials.8-10 The main
goal in the clinical trials was to establish the safety and
efficacy of sonothrombolysis. As was evident from these
studies, the efficacy of this method was not very encour-
aging, therefore its deployment was not that impressive
compared with the preclinical studies. Additionally, some
side effects reported delayed the full deployment of this
method.
This review is divided into 3 categories (in vitro, in
vivo, and clinical) and provides a comprehensive com-
pilation of protocols used during sonothrombolysis studies
with or without thrombolytic drugs and/or microbubbles
(MBs) since 1992. The aim of the review is to provide
information regarding (1) the clot model used (human
or animal for the in vitro studies and type of occlusion
for the animal and clinical studies), (2) the US tech-
nique applied such as external or internal (catheter based)
and focused or unfocused, (3) the use of flow system (only
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in vitro), (4) the temperature (only in vitro), (5) the type
and concentration of thrombolytic drug used, (6) the treat-
ment mode (US alone, drug alone, US + drug and
US + drug + MBs), (7) the sonication parameters applied,
such as frequency, intensity or acoustic power or nega-
tive pressure, pulse repetition frequency (PRF), duty factor
(DF), and treatment time, (8) the evaluation method used
to estimate study’s outcome, (9) the effect of treatment
on clot lysis, and (10) the main conclusions derived.
There is an absence in standardization about the nec-
essary information collected from each study due to
different methods/measuring units used by the investi-
gators. For example, the output of US transducer is
specified in different units (intensity, acoustic power, neg-
ative pressure, etc.), and the treatment’s outcome is
quantified by different evaluation methods such volume
reduction, fibrin degradation products, lytic rate, recana-
lization rate, etc. Furthermore, in some cases experimental
parameters like temperature, PRF and DF are not speci-
fied. This lack of standardization makes the comparison
among various studies impossible. Additionally, al-
though some impressive results were reported in the in
vitro and in the animal studies, the outcomes of the clin-
ical results were not that impressive. This could be
attributed to the fact that in some studies, thermal effects
were possibly reached, causing acceleration of
sonothrombolysis, which, however, eventually pro-
duced severe side effects.
Materials and Methods
Published reports on sonothrombolysis that are avail-
able in PubMed (www.ncbi.nlm.nih.gov/pubmed) were
collected. Information in several aspects of the proto-
cols used in the studies examined were also extracted.
In animal studies as well as in clinical trials, the follow-
ing information was needed: clot model, thrombolytic drug
and concentration, treatment mode, MBs administra-
tion, frequency, intensity or acoustic power or negative
pressure, PRF, DF, treatment time, evaluation method, treat-
ment’s outcome, side effects, and main conclusions. In
the in vitro compilation, the additional information needed
was temperature.
Results
Table 1 lists the in vitro studies, Table 2 lists the in
vivo studies, and Table 3 lists the clinical studies. The 3
tables include a comprehensive summary of all the issues
involved in sonothrombolysis. These main issues are (1)
the clot model used (human, animal, or in vitro), (2) type
of occlusion (for animal and clinical models), (3) the cou-
pling technique used (external or internal), (4) US modality
(focused or unfocused), (5) the use of flow system (only
for the in vitro studies), (6) indication of temperature (only
for the in vitro studies), (7) the type of thrombolytic drug
used, (8) concentration of thrombolytic drug used, (9) treat-
ment mode (US alone, drug alone, US + drug and
US + drug + MBs), (10) the applied frequency, (11) the
applied intensity or acoustic power or negative
pressure, (12) the applied PRF, (13) the applied DF, (14)
the treatment time, (15) the evaluation method used to
estimate the efficacy of sonothrombolysis, (16) the effect
of treatment on clot lysis, and (17) the main conclusions
derived.
In the in vitro studies the most common clot model
used was the human model (e.g., References 1-3, 12, and
13). In some cases the porcine model was used,4,48,54,56-58
the rabbit model,46,53 and the bovine.45,49 The intensity used
ranged from .5 W/cm2 to 193 W/cm2. The frequency used
varied from 20 KHz to 2 MHz, whereas in most experi-
ments the frequency used was about 1 MHz. The most
typical thrombolytic drug used was the recombinant tissue
plasminogen activator (rt-PA). In a few studies the uro-
kinase (UK) was used.21,25,32,36 The concentration of the rt-
PA varied from .1 to 100 µg/mL. In most of the studies
the drug concentration is specified as µg/mL, and in some
studies the IU/mL is specified. The treatment time used
varied from .5 minutes to 720 minutes, whereas the ma-
jority of the studies used treatment time between 30 and
60 minutes. We have observed that in a few studies the
clot temperature was not specified (e.g., References 36,
41, and 45). Based on 1 study,34 it is apparent that tem-
perature plays an important role in sonothrombolysis and
should be specified in all in vitro studies.
In the animal studies the most common clot models
used were the rabbit model5,6,48,64-74,78-80 and the rat
model.1,7,63,75 In the popular rabbit model the most com-
monly used artery was the femoral, followed by the middle
cerebral artery (MCA) and the carotid. The frequency used
varied from 20 kHz to 5.7 MHz, whereas in most experi-
ments the frequency used was about 1 MHz. The most
typical thrombolytic drug used was the rt-PA. In a few
studies the streptokinase was used.66,70,80 The concentra-
tion of the drug varied from .8 to 10 µg/mL. Clearly the
doses used in animals were much lower than those used
in the in vitro models. Most of the studies have evalu-
ated the effect of US alone, thrombolytic drug alone, or
the synergy of the 2 (US and drug). In most of the studies
the intensity is specified, and in some studies the pres-
sure is specified. The treatment time used varied from
2 minutes to 120 minutes, whereas the majority of the
studies used treatment time of 60 minutes. Compared with
the in vitro studies, in the animal studies, the addition-
al parameter used was the inclusion of MBs. Several
studies71-73,78-80 have shown that MBs may enhance the
sonothrombolysis efficiency.
In all the human trials evaluated the clot model used
was the MCA. The frequency used varied from 300 kHz
to 4 MHz. In all the studies the thrombolytic drug used
was the rt-PA. The concentration of the drug was .9 µg/
mL, which seems to be the safe dose used in humans.
Table 1. In vitro protocols used in sonothrombolysis
Clot model Drug
Temp.
(°C)
Mode
MBs Freq. Output PRF (Hz)
DF
(%)
Time
(min)
Evaluation
method Main conclusion Ref.
US
alone
Drug
alone US + drug
Human rt-PA
(3000 IU/mL)
37 Yes 50 Measured volume
reduction
33% 1
Yes 1 MHz 1.75 W/cm2
ISATA
Intermittent 50 50 50%
Yes 200 62%
Yes 1 MHz 1.75 W/cm2
ISATA
Intermittent 50 200 91% US combined with rt-PA caused a
significant enhancement of
thrombolysis compared with rt-PA
alone.
Human rt-PA
(1 µg/mL)
37 Yes 60 Measured volume
reduction
8% 2
Yes 27 kHz 1 W/cm2 70 10 60 17%
Yes 40 kHz 1 W/cm2 70 10 60 20%
Yes 100 kHz 1 W/cm2 70 10 60 15% US in the range of 27 to 100 kHz
is effective in accelerating fibrinolysis
at intensities and pulsing conditions
that minimize the probability of heating
and cavitation.
Human rt-PA
(3000 IU/mL)
36 Yes 60 Measured volume
reduction
22.7% 11
Yes 2 MHz 1.2 W/cm2 cw 100 60 49% (Traveling)
Yes 2 MHz 1.2 W/cm2 cw 100 60 34.8% (Standing)
Yes 2 MHz 1.2 W/cm2 1, 10, 100,
1000
50 60 46.4%, 39.8%, 44%, 34% Intermittent
application of a 2-MHz high-frequency
US using a traveling wave field would
be the most potent application for
lysing blood clots. No effect of PRF on
clot lysis.
Human rt-PA
(3000 IU/mL)
37 Yes 1.95 MHz 1.2 W/cm2
ISATA
1 50 60 Measured volume
reduction
25.3% 3
Yes 60 19.9%
Yes 1.95 MHz 1.75 W/cm2
ISATA
1 50 60 35.2% US enhances thrombolysis by
affecting the distribution of rt-PA
within the clot.
Human rt-PA
(3.15 µg/mL)
37 Yes 30 Measured lytic rate .5 µm/min 12
Yes 120 kHz .35 MPa 1667 80 30 3.4 µm/min US treatment + rt-PA
significantly enhanced the mean lytic
rate (580% change), compared with
rt-PA treatment alone.
Human rt-PA
(3.15 µg/mL)
37 Yes 30 Measured lytic rate 7 µm/min 13
Yes 120 kHz .35 MPa 1667 10, 20,
50, 80
30 15, 25, 50, 65 µm/min The lytic
efficacy of clots exposed to rt-PA and
US increases with increasing DF.
Porcine rt-PA
(107 µg/mL)
37 Yes 30 Measured volume
reduction
12% 4
Yes 120 kHz .35 MPa 1.7 k 80 30 19.1%
Yes 1 MHz .35 MPa 1.7 k 100 30 25%
Yes 1 MHz .35 MPa 1.7 k 10 30 22% Both 120-kHz and 1-MHz pulsed
and c.w. US enhanced rt-PA
thrombolysis in a porcine whole blood
clot model.
(continued on next page)
Table 1. (continued)
Clot model Drug
Temp.
(°C)
Mode
MBs Freq. Output PRF (Hz)
DF
(%)
Time
(min)
Evaluation
method Main conclusion Ref.
US
alone
Drug
alone US + drug
Human rt-PA
(10 µg/mL)
37 Yes 30 Measured volume
reduction
16% 14
Yes 120 kHz .35 MPa 1667 50 30 31% 120-kHz US substantially
increases the lytic efficacy of rt-PA for
almost all rt-PA concentrations.
Human rt-PA
(3.15 µg/mL)
37 Yes 30 Measured volume
reduction
31% 15
Yes 120 kHz .35 MPa 1667 50 30 71%
Yes Yes
(t-ELIP)
30 48%
Yes Yes
(t-ELIP)
120 kHz .35 MPa 1667 50 30 89% The addition of 120 kHz US with
t-ELIP substantially increases the rate
of lysis compared with either tPA or
t-ELIP alone.
Human rt-PA
(.5-3.15 µg/mL)
37 Yes 30 Measured volume
reduction
38%-44% 16
Yes 120 kHz .18 MPa 1667 50 30 50%-70%
Yes 2 MHz .47 MPa 10.5 k 13 30 52%-58% Combination treatment with
rt-PA is more effective than rt-PA alone
in human whole blood clots.
Fibrin gel rt-PA
(.1 µg/mL)
25 Yes 1 MHz 2 W/cm2 100 50 Measured binding
ratios
US exposure accelerates rt-PA binding,
alters binding affinity, and increases
maximum binding to polymerized
fibrin
17
Fibrin gel Yes 1 MHz 4 W/cm2 c.w. 100 15 Measured fiber
density
Measured fiber
diameter
>65% 18
<27% US exposure causes reversible
disaggregation of uncross-linked fibrin
fibers into smaller fibers, an effect that
may alter flow resistance and create
additional binding sites for fibrinolytic
components, improving fibrinolytic
efficacy.
Human rt-PA
(.1 µg/mL)
37 Yes 240 Measured uptake
rate
8.2% 19
Yes 1 MHz 4 W/cm2 c.w. 100 240 15.5% Exposure to US increases uptake
of rt-PA into clots and also results in
deeper penetration.
Human rt-PA
(2 µg/mL)
Yes 60 Measured fibrin
degradation
product, D-dimer
(FDP-DD)
957 ng/mL 20
Yes 300 kHz .07 W/cm2 c.w. 100 60 1669 ng/mL
Yes 1 MHz .4 W/cm2 c.w. 100 60 1727 ng/mL The combination of drug
and US leads to degradation of fibrin,
allowing a quantitative measurement of
the enhancement of clot lysis. A high
correlation was observed between the
FDP-DD produced with the rate of
decrease in clot weight.
Human
flow
system
UK
(400 U/mL)
37 Yes 60 Measured volume
reduction
18.7% 21
Yes 1 MHz 2.5 W/cm2 c.w. 100 60 52.5% c.w. US at 1 MHz and an
intensity of 2.5 W/cm2 accelerates
urokinase-induced thrombolysis and
reperfusion.
(continued on next page)
Table 1. (continued)
Clot model Drug
Temp.
(°C)
Mode
MBs Freq. Output PRF (Hz)
DF
(%)
Time
(min)
Evaluation
method Main conclusion Ref.
US
alone
Drug
alone US + drug
Human SK
(5000 U/mL)
37 Yes 65 Measured
reperfusion rate
100% 22
Yes 170 kHz .5 W/cm2
(ISATA)
c.w. 100 34 100%
Yes 39 100%
Yes 1 MHz 1 W/cm2
(ISATA)
c.w. 100 20 100% US exposure of a type and
intensity that may be transmitted
transthoracically accelerates the
thrombolytic process (for both
frequencies used).
Human
HIFU
rt-PA
(10 µg/mL)
37 Yes 1 MHz 60 W 1 10 30 Measured volume
reduction
33% 23
Yes 30 53.1%
Yes 1 MHz 60 W 1 10 30 63.2% The rate of tPA-mediated
thrombolysis can be enhanced by using
pulsed HIFU exposure.
Human rt-PA
(1.0 µg/mL)
37 Yes 60 Measured volume
reduction
12.8% 24
Yes 1 MHz 1, 2, 4,
8 W/cm2
c.w. 100 60 18%, 19.3%, 22.8%, 58.7% US at
1 MHz potentiates enzymatic
fibrinolysis by a nonthermal
mechanism. Thrombolysis efficiency
increases with intensity.
Human UK (200, 2000,
5000 µg/mL)
Room Yes 1 MHz 2.2 W/cm2 n/s n/s 30 Measured volume
reduction
18% 25
Yes 30 19%, 44%, 50%
Yes 1 MHz 2.2 W/cm2 n/s n/s 30 41%, 55%, 61%
SK (50, 250,
2000 µg/mL)
Yes 1 MHz 2.2 W/cm2 n/s n/s 30 26%
Yes 30 37%, 50%, 62%
Yes 1 MHz 2.2 W/cm2 n/s n/s 30 45%, 61%, 73% The use of external US
has the potential to increase both
efficacy and rate of thrombolysis.
Thrombolysis efficiency increases with
drug dose. Thrombolytic activity of SK
more effective than UK.
Human rt-PA
(1.0 µg/mL)
37 Yes 60 Measured volume
reduction
23% 26
Yes 2.2 MHz .5, 1, 2, 4,
8 W/cm2
n/s n/s 60 31%, 40%, 48%, 69%, 88% US
accelerates enzymatic fibrinolysis by
increasing transport of reactants
through a cavitation-related
mechanism. Thrombolysis efficiency
increases with intensity.
Human rt-PA
(66.7 µg/mL)
37 Yes 25 Measured volume
reduction
7.24% 27
Yes .5 MHz 8 W/cm2 c.w. 100 25 26.7% US waves accelerate rt-PA-
induced thrombolysis and reperfusion.
(continued on next page)
Table 1. (continued)
Clot model Drug
Temp.
(°C)
Mode
MBs Freq. Output PRF (Hz)
DF
(%)
Time
(min)
Evaluation
method Main conclusion Ref.
US
alone
Drug
alone US + drug
Human rt-PA
(1 µg/mL)
37 Yes 60, 120 Measured volume
reduction
13%, 37% 28
Yes 40 kHz .25 W/cm2 c.w. 100 60, 120 39%, 93%
Yes 40 kHz .75, 1,
1.5 W/cm2
c.w. 100 60 58%, 75%, 77% 40-kHz US
significantly accelerates enzymatic
fibrinolysis with excellent tissue
penetration and minimal heating.
Thrombolysis efficiency increases with
intensity.
Human rt-PA
(3000 U/mL)
37 Yes 60 Measured volume
reduction
23.8% 29
Yes 1 MHz 1.2 W/cm2 c.w. 100 60 34.8 (Standing)
Yes 60 11.3%
Yes 2 MHz 1.2 W/cm2 c.w. 100 60 24.5% (Traveling) Traveling US waves
enhanced thrombolysis (116.8%),
which is significantly more than
standing US waves did (46%).
Human rt-PA
(3 µg/mL)
37 Yes 20 kHz .35 W/cm2 c.w. 100 10 Measured volume
reduction
41.8% 30
Yes 20 49.1%
Yes 20 kHz .35 W/cm2 c.w. 100 10 65.8% The use of low-frequency US
alone has the potential to induce
thrombolysis. Combination of US with
rt-PA is superior to either treatment
alone.
Human rt-PA
(3.15 µg/mL)
37 Yes 30 Measured volume
reduction
15.6% 31
Yes + Epf. 30 28%
Yes 120 kHz .18 MPa 1667 80 30 44.4%
Yes + Epf. 120 kHz .18 MPa 1667 80 30 30.3% Although the addition of
eptifibatide enhances the lytic efficacy
of rt-PA alone, the efficacy of US and
rt-PA is greater than that of combined
US, rt-PA, and eptifibatide exposure.
Human UK
(2 mg/mL)
37 Yes 720 Measured volume
reduction
43% 32
Yes 211.5 kHz .25 W/cm2 c.w. 100 720 61% Low-frequency US transmits well
through human temporal bone and
enhances thrombolysis.
Human
through
skull
rt-PA
(100 µg/mL)
37 Yes 33.3 kHz .5 W/cm2 n/s n/s 60, 180 Measured volume
reduction
39.96%, 44.09% 33
Yes 71.4 kHz 3.4 W/cm2 n/s n/s 60, 180 32.24%, 35.17%
Yes 60, 180 46.55%, 56.27%
Yes 33.3 kHz .5 W/cm2 n/s n/s 60, 180 51.04%, 67.89%
Yes 71.4 kHz 3.4 W/cm2 n/s n/s 60, 180 46.23%, 60.47% Transcranial
application of US can shorten the
recanalization time of intracerebral
vessel occlusion by increasing rt-PA-
mediated thrombolysis. Thrombolysis
efficiency increases with time.
(continued on next page)
Table 1. (continued)
Clot model Drug
Temp.
(°C)
Mode
MBs Freq. Output PRF (Hz)
DF
(%)
Time
(min)
Evaluation
method Main conclusion Ref.
US
alone
Drug
alone US + drug
Human rt-PA
(3.15 µg/mL)
33, 37 Yes 120 kHz 3.2 W/cm2 1667 80 30 Measured volume
reduction
7.5%, 7.2% 34
Yes 30 8.6%, 12.4%
Yes 120 kHz 3.2 W/cm2 1667 80 30 21.2%, 22.7% The efficacy of US
enhanced thrombolysis decreases at
temperatures below the body baseline
temperature of 37°C.
Human
through
temporal
bone
rt-PA
(10 µg/mL)
37 Yes 1.8 MHz 1.6 MI n/s n/s 60 Measured volume
reduction
41% 70.8% 35
Yes 60 78.7%
Yes 1.8 MHz 1.6 MI n/s n/s 60 Diagnostic transcranial US with rt-PA,
enhances thrombolysis.
Human
through
skull
HIFU flow
system
n/s Yes 220 kHz 111 W/cm2 2.5 50 .5 Measured volume
reduction
76.1% (Flow) 36
n/s Yes 220 kHz 111 W/cm2 2.5 50 .5 29.9% (No flow) Trans-skull HIFU for
immediate clot lysis without the need
of further drugs and disregarding
individual skull bone characteristics is
feasible.
Human UK
(1200 IU)
37 Yes 60 Measured volume
reduction after
incubation
40.6% 37
Yes 48 kHz 5-6 kPa n/s n/s 60 59.2%
Yes 60, 120 8.9%, 46.7%
Yes 225 kHz 30 mW/cm2 n/s n/s 60, 120 37.3%, 61.1% US energy enhanced
fibrinolysis with UK, especially in the
early phase of lysis. Thrombolysis
efficiency increases with time and
decreases with frequency.
Bovine
through
skull flow
system
rt-PA
(100 µg/mL)
37 Yes 29.3 Measured
recanalization rate
100% 38
37 Yes 1 MHz .35 W/
cm2(ISPTP)
16 k 41.6 17.1 100%
Yes 185 kHz 1.27 W/cm2
(ISPTP)
c.w. 100 14.1 100% Transcranial application of low
frequency, c.w. US may accelerate
reperfusion and shorten the
recanalization time.
Bovine
through
skull flow
system
rt-PA
(100 µg/mL)
37 Yes 30 Measured
recanalization rate
30% 39
Yes 1 MHz .35 W/cm2
(ISPTP)
16,000 41.6 30 90%-100% Transcranial application of
1 MHz US may accelerate reperfusion
and recanalization rate of occluded
intracerebral vessels.
Human
through
skull
HIFU flow
system
24 Yes 220 kHz 13.7,
27.4, 54.8,
136.8 W/cm2
(ISPTA)
.5, 5, 50,
500
5, 10,
20, 50
.5 Measured volume
reduction
10.3%-27.2%
17.1%-42.9%
30%-59.6%
48.7%-59.2% Using transcranial HIFU,
significant thrombolysis can be
achieved within seconds and without
the use of lytic drugs. Longer DF in
combination with longer p.w. seems to
have the highest potential to optimize
clot lysis efficacy.
40
(continued on next page)
Table 1. (continued)
Clot model Drug
Temp.
(°C)
Mode
MBs Freq. Output PRF (Hz)
DF
(%)
Time
(min)
Evaluation
method Main conclusion Ref.
US
alone
Drug
alone US + drug
Human
FUS
n/s Yes 550 kHz 200 W 3.7 10 5 Measured volume
reduction
80% 41
Yes 535 and
565 kHz
110 W 3.7 10 5 80% The power needed to achieve 80%
of thrombolysis with a monofrequency
excitation is reduced by half with a
bifrequency excitation.
Human rt-PA
(60 kU/mL)
37 Yes 60 Measured volume
reduction
36.7% 42
Yes 2 MHz
TCCD
.179 W/cm2 n/s n/s 60 40.8%
Yes 2 MHz
TCD
.457 W/cm2 n/s n/s 60 40.4% Although clot lysis rate after 1-h
treatment with rt-PA alone was
significant, a slight increase of weight
loss was detected under the application
of US + drug.
Human
HIFU
37 Yes 230 kHz 1000 W 1000 10 .5 Measured volume
reduction
82% After sonication, the clot was
nearly completely lysed.
43
Human
through
skull
HIFU flow
system
37 Yes 220 kHz 29.71-
193.24 W/cm2
(ISPTA)
2.5 50 .5 Measured volume
reduction
4.55%-74.83% Transcranial
sonothrombolysis could be achieved
within seconds in the absence of rt-PA
and without producing relevant clot
fragmentation, using acoustic output
powers of <400 W.
44
Bovine n/s Yes 500 kHz ISPTA > 35 W/
cm2
200 4 4 Measured volume
reduction
91% External HIFU thrombolysis for
periods of ≤5 min appears to be a safe
and effective method to induce
thrombolysis.
45
Rabbit
flow
model
Room Yes 1.51 MHz 185 W 1 .1 .33 Measured volume
reduction
99.2% HIFU thrombolysis is feasible as
a means of restoring partial blood flow
in thrombus occluded arteries in the
absence of thrombolytic agents.
46
Human rt-PA
(10 µg/mL)
37 Yes 1 MHz 4 W/cm2
(ISATA)
c.w. 100 60 Measured volume
reduction
6.8% at 0 atm 47
Yes 60 21.8% at 0 atm
Yes 1 MHz 4 W/cm2
(ISATA)
c.w. 100 60 39.3% at 0 atm US is ineffective in
increasing fibrinolysis without a
fibrinolytic agent present. An 80%
increase in clot lysis occurs when US
and agent are both present (no
overpressure).
Porcine rt-PA
(107 µg/mL)
37 Yes 30 Measured volume
reduction
13% 48
Yes 120 kHz .15 MPa 1667 80 30 13.7% (<SC)
Yes 120 kHz .24 MPa 1667 80 30 26% (SC)
Yes 120 kHz .36 MPa 1667 80 30 20.7% (SC + IC) Significant
enhancement of thrombolysis correlates
with presence of cavitation. Stable
cavitation appears to play a more
important role in the enhancement of
thrombolysis.
(continued on next page)
Table 1. (continued)
Clot model Drug
Temp.
(°C)
Mode
MBs Freq. Output PRF (Hz)
DF
(%)
Time
(min)
Evaluation
method Main conclusion Ref.
US
alone
Drug
alone US + drug
Human
catheter
type flow
system
rt-PA
(300 µg/mL)
37 Yes 10 Measured volume
reduction
13.6% 49
Yes 1.7 MHz 62.46 W/cm2
(ISPPA)
30 8.5 10 21.4%
Yes 1.7 MHz 180.02 W/cm2
(ISPPA)
40 4 10 46.1% Thrombolysis efficiency
increases with intensity.
Human rt-PA
(96 µg/mL)
37 Yes Yes 120 kHz .32 MPa 1667 80 30 Measured volume
reduction
6.3% 50
Yes 30 13.0%
Yes 120 kHz .32 MPa 1667 80 30 16.0%
Yes Yes 120 kHz .32 MPa 1667 80 30 26.2% MBs administration further
increases the effect of US on rt-PA
induced thrombolysis.
Bovine rt-PA
(1000 IU/mL)
37 Yes Yes 500 kHz .7 W/cm2 c.w. 100 1 Measured volume
reduction
25.8% 49
Yes 1 24.2%
Yes 500 kHz .7 W/cm2 c.w. 100 1 24.9%
Yes Yes 500 kHz .7 W/cm2 c.w. 100 1 29.2% MBs have slightly accelerated
the thrombolytic effect of rt-PA.
Human
Catheter
type
rt-PA
(5000 IU/mL)
37 Yes Yes 1.7 MHz 4.9 W/cm2
ISATA
n/s n/s 30 Measured volume
reduction
.95% 51
Yes 30 7.68%
Yes 1.7 MHz 4.9 W/cm2
ISATA
n/s n/s 30 11.10%
Yes Yes 1.7 MHz 4.9 W/cm2
ISATA
n/s n/s 30 14.41% SC plays an important role in
MB-enhanced US accelerated rt-PA-
mediated thrombolysis.
Human
flow
system
rt-PA
(20 µg/mL)
37 Yes 2 MHz 455 mW/cm2
ISPTA
5000 n/s 30 Measured volume
reduction
6.1% 52
Yes Yes 455 mW/cm2
ISPTA
5000 n/s 30 10.9%
Yes 2 MHz 455 mW/cm2
ISPTA
5000 n/s 30 13.1%
Yes Yes 2 MHz 455 mW/cm2
ISPTA
5000 n/s 30 30.7% The application of MBs strongly
accelerates lysis of clots exposed to
low-intensity US with rt-PA.
Rabbit 25 Yes Yes
(3 µm)
1 MHz .1 W/cm2 100 20 30 Measured volume
reduction
18% 53
Yes Yes
(1 µm)
3 MHz 2 W/cm2 100 20 30 18% Sonothrombolysis efficacy was
achieved at 20-fold lower intensity with
3 µm MBs (.1 W/cm2) than with 1 µm
MBs (2.0 W/cm2).
Porcine
flow
system
rt-PA
(7.1 µg/mL)
37 Yes 30 Measured volume
reduction
29% 54
Yes Yes 120 kHz .44 MPa c.w. 100 30 34%
Yes Yes 120 kHz .44 MPa c.w. 100 30 83% (SC) SC nucleated by an infusion
of MBs enhances rt-PA thrombolysis
without apparent treatment-related
damage.
(continued on next page)
Table 1. (continued)
Clot model Drug
Temp.
(°C)
Mode
MBs Freq. Output PRF (Hz)
DF
(%)
Time
(min)
Evaluation
method Main conclusion Ref.
US
alone
Drug
alone US + drug
Human
flow
system
rt-PA
(3 µg/mL)
37 Yes 60 Measured clot
diameter loss
6.6 µm/min 55
rt-PA
(.3 µg/mL)
Yes Yes 1.6 MHz 600 kPa .33 33 60 5.9 µm/min Τhe combination of US,
MB, and a low dose of rt-PA (.3 µg/
mL) is as effective for thrombolysis as
is a high dose of rt-PA (3 µg/mL) alone.
Porcine
flow
system
rt-PA
(3 µg/mL)
37 Yes 30 Measured volume
reduction
25.6% 56
Yes Yes 1 MHz 1 MPa .2 .002 30 55.7% The US + MB + rt-PA treatment
showed dramatically higher lytic
efficacy than rt-PA treatment alone.
Porcine
Flow
system
rt-PA
(1 µg/mL)
37 Yes Yes 1 MHz 1.5 MPa .34 .17 20 Measured lytic
efficacy In terms of
pressure change
(thrombotic
occlusion = 40 mm
Hg)
6 mm Hg 57
Yes Yes 1 MHz 1 MPa .34 .17 20 2 mm Hg Similar lytic efficacy was
achieved at 1.5 MPa without rt-PA as
was at 1.0 MPa with rt-PA.
Porcine
flow
system
Yes Yes 1.6 MHz .2 (MI) n/s n/s 10 Measured volume
reduction
54% (20 µs PD) 58
Yes Yes 1.6 MHz .2 (MI) n/s n/s 10 33% (5 µs PD) Slightly prolonging the
pulse duration (PD) on a diagnostic
transducer improves the degree of
sonothrombolysis that can be achieved
without fibrinolytic agents at a lower
MI.
Human
flow
system
rt-PA
(.32-3.15 µg/mL)
37.3 Yes 10 Measured lytic rate .8%-2%/min 59
Yes 120 kHz .44 MPa Inter. 62.5 30 .8%-2%/min
Yes Yes 120 kHz .44 MPa Inter. 62.5 30 2-5%.5%/min MBs administration
significantly enhanced lytic rate. Both
SC and radiation force are
mechanistically responsible for the
process of clot lysis.
Human
flow
system
rt-PA
(3 µg/mL)
37 Yes 60 Measured fibrin
degradation
product (FDP)
51.7% 60
Yes Yes 1 MHz 528 mW/cm2
ISPTA
.8 40 60 53.2% (SC)
Yes Yes 1 MHz 323 mW/cm2
ISPTA
.8 8 60 57.2% (SC + IC)
Yes Yes 1 MHz 3 mW/cm2
ISPTA
.8 .08 60 50.9% (SC + IC)
Yes Yes 1 MHz 45 mW/cm2
ISPTA
.8 .08 60 66.3% (IC) Both SC and IC, resulting
from the US–MB interaction, increased
the efficacy of rt-PA with respect to
fibrin degradation.
(continued on next page)
Table 1. (continued)
Clot model Drug
Temp.
(°C)
Mode
MBs Freq. Output PRF (Hz)
DF
(%)
Time
(min)
Evaluation
method Main conclusion Ref.
US
alone
Drug
alone US + drug
Porcine
FUS flow
system
rt-PA
(3.5 µg/mL)
37 Yes Yes 1 MHz 20 W 100 10 30 Measured volume
reduction
31% 61
Yes 30 45%
Yes 1 MHz 20 W 100 10 30 56.2%
Yes Yes 1 MHz 20 W 100 10 30 69.5% MBs administration further
enhanced the beneficial effect of FUS
on TNK-tPA mediated thrombolysis.
Human
flow
system
rt-PA
(7 µg/mL)
37 Yes 30 Measured volume
reduction
29.2% 62
Yes .6 MHz 60 W 100 10 30 45.8%
Yes 1 MHz 20-60 W 100 10 30 39%-62.5%
Yes Yes 1 MHz 60 W 100 10 30 87.5%
1 MHz FUS frequency is associated
with enhanced thrombolysis compared
with that of .6 MHz. An increased
linear relationship between acoustic
power and thrombolysis efficacy was
exhibited. The combination of
MBs + FUS strongly enhanced the
thrombolytic efficacy of TNK-tPA.
Abbreviations: Abib, abciximab immunobubbles; c.w., continuous wave; DF, duty factor; ELIP, echogenic liposomes; Epf., eptifibatide; Freq., frequency; FUS, focused ultrasound; HIFU, high-
intensity focused ultrasound; IA, intrarterial; IV, intravenous; MBs, microbubbles; MCA, middle cerebral artery; mt-PA, monteplase tissue plasminogen activator; n/s, not specified; Nsib, nonspecific
immunobubbles; PRF, pulse repetition frequency; p.w., pulsed wave; Ref., references; rt-PA, recombinant tissue plasminogen activator; sICH; symptomatic intracranial hemorrhage; SK, strepto-
kinase; TCD, transcranial Doppler; TCCD, transcranial color-coded duplex; Temp., temperature; TNK-tPA, tenecteplase tissue plasminogen activator; UK, urokinase; US, ultrasound.
Table 2. In vivo protocols used in sonothrombolysis
Clot model Drug
Mode
MBs Freq. Output PRF (Hz)
DF
(%)
Time
(min)
Evaluation
method Main conclusion
Side
effects Ref.
US
alone
Drug
alone US + drug
Rat
Jugular vein
occlusion
rt-PA (1 mg) Yes 50, 200 Measured volume
reduction
2%0, 30% 1
Yes 1 MHz 1.75 W/cm2 Intermittent 50 50, 200 41%, 55%
rt-PA (2 mg) Yes 50, 200 28%, 40%
Yes 1 MHz 1.75 W/cm2 Intermittent 50 50, 200 45%, 50%
Intermittent US administered during a
200-min period showed a trend toward
enhancement of rt-PA-induced
fibrinolysis without causing thermal
changes or inducing tissue damage.
Thrombolysis efficiency increased with
drug dose.
Rat
MCA stroke
rt-PA
(10 mg/kg)
Yes 60 Measured relative
infarct
volume reduction
34% 18% ICH 63
rt-PA
(5 mg/kg)
Yes 25.6 kHz .6 W/cm2 n/s 20 60 51%
rt-PA
(10 mg/kg)
Yes 25.6 kHz .6 W/cm2 n/s 20 60 68%
US treatment in addition to rt-PA is
more effective than single rt-PA
treatment in reducing infarct volume
and safe with regard to bleeding.
Thrombolysis efficiency increased with
drug dose.
20% ICH
Rabbit
Embolic
stroke
HIFU
Yes 1.5 MHz 255 W 1 .1 .33 Measured
reperfusion rate
0% (0/3) 64
Yes 1.5 MHz 415 W 1 .1 .33 50% (2/4)
Yes 1.5 MHz 550 W 1 .1 .33 70% (5/7)
HIFU, as a stand-alone method, can
cause effective thrombolysis and does
not damage the targeted vessels.
20% ICH
Rabbit
MCA
Stroke
HIFU
Yes Yes 1.5 MHz 88-137 W 1 .1 .33 Measured
recanalization rate
78% (7/9) 22% ICH 65
Yes Yes 1.5 MHz 88 W 10 .1 .33 50% (1/2)
Droplets reduce the IC threshold and
enable IC-mediated clot lysis to occur
at lower power levels.
Rabbit
Femoral artery
occlusion
HIFU
Yes 1.51 MHz 185 W 1 .1 .33 Measured flow
restoration rate
0% (0/5) 48
Yes 1.51 MHz 215 W 1 .1 .33 50% (1/2)
Yes 1.51 MHz 300 W 1 .1 .33 63% (5/8)
HIFU thrombolysis is feasible as a
means of restoring partial blood flow in
thrombus-occluded arteries in the
absence of thrombolytic agents.
Increased power resulted in increased
flow restoration rate.
13% ICH
(continued on next page)
Table 2. (continued)
Clot model Drug
Mode
MBs Freq. Output PRF (Hz)
DF
(%)
Time
(min)
Evaluation
method Main conclusion
Side
effects Ref.
US
alone
Drug
alone US + drug
Rabbit
Iliofemoral
artery
occlusion
SK
(25000 U/kg)
Yes 37 kHz 160 W 91 n/s 15 Measured
recanalization rate
40% (6/15) 66
Yes 37 kHz 160 W 91 n/s 30 67% (10/15)
Yes 37 kHz 160 W 91 n/s 45 87% (13/15)
Yes 37 kHz 160 W 91 n/s 60 100% (15/15)
Transcutaneous concentrated US which
significantly enhances streptokinase
induced thrombolysis in vivo can be
delivered without concomitant tissue
damage. Recanalization rate increases
with treatment time.
Rabbit
Iliofemoral
artery
occlusion
Yes 37 kHz 160 W 91 n/s 60 Measured
recanalization rate
0% (0/5) 67
Yes 37 kHz 160 W 91 n/s 60 0% (0/10)
Yes Yes 37 kHz 160 W 91 n/s 15 30% (3/10)
Yes Yes 37 kHz 160 W 91 n/s 30 50% (5/10)
Yes Yes 37 kHz 160 W 91 n/s 45 70% (7/10)
Yes Yes 37 kHz 160 W 91 n/s 60 100% (10/10)
In vivo arterial clot dissolution can be
achieved with IV MBs and
transcutaneous US. Recanalization rate
increased with treatment time.
Rabbit
Marginal ear
vein occlusion
HIFU
rt-PA
(1 mg/kg)
Yes 1 MHz 40 W 1 5 15 Measured relative
clot size at 5 h post
treatment
90% 5
Yes 15 78%
Yes 1 MHz 40 W 1 5 15 4%
rt-PA-mediated thrombolysis can be
significantly enhanced when combined
with noninvasive pulsed-HIFU
exposures.
Rabbit
Femoral artery
occlusion
SK
(15,000 U/
kg) bolus
followed by
an infusion
of 15,000 U/
kg/h.
Yes 120 Measured volume
reduction
13% (2/15) 6
Yes 1 MHz 2 W/cm2 c.w. 120 53% (9/17)
Externally applied, low-intensity US
can significantly enhance thrombolysis
in a rabbit arterial model.
Rabbit
Femoral artery
occlusion
rt-PA
(200 µg/
5 mg of
lipid)
Yes Empty
ELIP
5.7 MHz 1.25 MPa 5 k n/s 2 Measured
recanalization rate
at 15 min post
treatment
27% 68
Yes rt-PA
ELIP
rt-PA
ELIP
2 60%
Yes 5.7 MHz 1.25 MPa 5 k n/s 2 100%
Doppler US treatment enhances the
thrombolytic effect of rt-PA loaded
ELIP, resulting in earlier and more
complete recanalization rates.
(continued on next page)
Table 2. (continued)
Clot model Drug
Mode
MBs Freq. Output PRF (Hz)
DF
(%)
Time
(min)
Evaluation
method Main conclusion
Side
effects Ref.
US
alone
Drug
alone US + drug
Rat
MCA stroke
rt-PA
(1.2 mg/
animal)
Yes 32 Measured volume
reduction
45% (9/20) 7
Yes 490 kHz .8 W/cm2 c.w. 100 32 76.2% (16/21)
Low-frequency transcranial US under
appropriate conditions could be an
effective and safe method of treatment
for ischemic stroke.
Rabbit
Femoral artery
occlusion
mt-PA
(1.2 mg/
animal)
Yes 32 Measured
recanalization rate
16.7% (2/12) 69
Yes 490 kHz .13 W/cm2 c.w. 100 32 66.7% (6/9)
Low-frequency and low-intensity
transcranial US enhanced thrombolysis
by mt-PA.
Rabbit
Femoral artery
occlusion
SK
(15,000 U/
kg) as bolus
followed by
an infusion
of
15,000 U/
kg/h
Yes 40 kHz .75 W/cm2 c.w. 100 120 Measured
reperfusion rate
<7% 70
Yes 120 7%
Yes 40 kHz .75 W/cm2 c.w. 100 120 83%
40-kHz US at low intensity markedly
accelerates fibrinolysis and also
improves tissue perfusion and reverses
acidosis, effects that would be
beneficial in treatment of acute
thrombosis.
Rabbit
MCA stroke
HIFU
rt-PA (1.mg/
ml/kg)
Yes 120 Measured
recanalization rate
100% 71
Yes Yes 1 MHz 20 W/cm2
(ISATA)
10 10 70 100%
HIFU in combination with rt-PA
dissolved clots.
Rabbit
MCA stroke
HIFU
rt-PA (1.mg/
ml/kg)
Yes Yes 1 MHz 20 W/cm2
(ISATA)
10 10 70 Measured
recanalization rate
100%
Therapeutic US in synergy with rt-PA
dissolve clots.
72
Rabbit
Hindlimb
occlusion
Yes Yes 1 MHz .031 W/cm2
(ISATA)
.33 .17 10 Measured
recanalization rate
67% 73
Yes Yes 1 MHz .031 W/cm2
(ISATA)
.33 .17 20 100%
Long-pulse-length US with MBs has a
therapeutic effect on microvascular
perfusion.
Rabbit
Femoral artery
occlusion
rt-PA
(30 µg/kg/
min)
Yes 74 Measured initial
reflow
15%-50% 74
Yes 1 MHz 6.3 W/cm2
ISPTA
c.w. 100 33 15%-50%
Although time to initial reflow was
shortened by US, it was associated with
less reperfusion and more reocclusion
in this model.
(continued on next page)
Table 2. (continued)
Clot model Drug
Mode
MBs Freq. Output PRF (Hz)
DF
(%)
Time
(min)
Evaluation
method Main conclusion
Side
effects Ref.
US
alone
Drug
alone US + drug
Rat
MCA stroke
rt-PA
(10 mg/kg)
Yes 1-3 MHz 1.7 (MI) n/s n/s 60 Measured
recanalization rate
40% 75
Yes Yes 1-3 MHz 1.7 (MI) n/s n/s 60 59%
Yes 60 77%
Yes 1-3 MHz 1.7 (MI) n/s n/s 60 88%
Yes Yes 1-3 MHz 1.7 (MI) n/s n/s 60 96%
Recanalization rate with rt-PA alone is
better than US alone. Recanalization
rate significantly increased with the
combination of US + drug.
Recanalization rate increased even
more when US was combined with
rt-PA + MBs.
Rat
Carotid artery
occlusion
Yes 2 MHz 1.56 MPa 150 5 30 Measured plasma
D-dimer
concentrations
1.70 µg/mL 76
Yes Yes
(Nsib)
2 MHz 1.56 MPa 150 5 30 2.31 µg/mL
Yes Yes
(Abib)
2 MHz 1.56 MPa 150 5 30 3.91 µg/mL
US in combination with abciximab
immunobubbles (Abib) induces
thrombolysis without lytic agents that
is superior to insonation of non-specific
immunobubbles (Nsib).
Rabbit
Embolic
stroke
rt-PA
(.8-0.9 mg/
kg)
Yes 1 MHz .8 W/cm2
(ISATA)
100 20 60 Measured infarct
volume
1% 56% ICH 77
Yes 1 MHz .8 W/cm2
(ISATA)
100 20 60 .13% 61% ICH
Yes Yes 1 MHz .8 W/cm2
(ISATA)
100 20 60 .2% 19% ICH
Yes Yes 1 MHz .8 W/cm2
(ISATA)
100 20 60 .09%
The ability of
MBs to reduce rt-PA requirements may
lead to lower rates of hemorrhage in
human stroke treatment.
26% ICH
Rabbit
Embolic
stroke
rt-PA
(.9 mg/kg)
Yes 60 Measured infarct
volume
2.2% 45% ICH 78
Yes 1 MHz .8 W/cm2 n/s 20 60 1.7% 50% ICH
Yes Yes 1 MHz .8 W/cm2 n/s 20 60 .8%
Sonothrombolysis without rt-PA using
MBs is effective in decreasing infarct
volumes.
36% ICH
(continued on next page)
Table 2. (continued)
Clot model Drug
Mode
MBs Freq. Output PRF (Hz)
DF
(%)
Time
(min)
Evaluation
method Main conclusion
Side
effects Ref.
US
alone
Drug
alone US + drug
Rabbit
Embolic
stroke
rt-PA
(.9 mg/kg)
Yes 1 MHz .8 W/cm2 n/s 20 60 Measured infarct
volume
.97% 56% ICH 79
Yes 60 .14% 48% ICH
Yes 1 MHz .8 W/cm2 n/s 20 60 .15% 73% ICH
Yes Yes 1 MHz .8 W/cm2 n/s 20 60 .20% 19% ICH
Yes Yes 1 MHz .8 W/cm2 n/s 20 60 .10%
Treatment with MB + US following
embolization decreased the incidence
of ICH and efficacy was similar to tPA
in reducing infarct volume.
36% ICH
Rabbit
Iliofemoral
artery
occlusion
SK
(25,000 U/
kg))
Yes 20 kHz 1.5 W/cm2 n/s n/s 60 Measured patency
rate
0% (0/6) 80
Yes 60 6% (1/17)
Yes 37 kHz 160 W n/s n/s 60 100% (15/15)
Yes Yes 20 kHz 1.5 W/cm2 n/s n/s 60 87% (13/15)
Yes Yes 20 kHz 1.5 W/cm2 n/s n/s 60 76% (13/17)
Yes Yes 37 kHz 160 W n/s n/s 60 Noninvasive transcutaneous US can
greatly enhance the effect of clot
dissolution with thrombolytic drugs
and/or MBs.
Abib, abciximab immunobubbles; c.w., continuous wave; DF, duty factor; ELIP, echogenic liposomes; Freq., frequency; HIFU, high-intensity focused ultrasound; IV, intravenous; MBs, microbubbles;
MCA, middle cerebral artery; mt-PA, monteplase tissue plasminogen activator; Nsib, nonspecific immunobubbles; n/s, not specified; PRF, pulse repetition frequency; Ref., references; rt-PA, re-
combinant tissue plasminogen activator; SK, streptokinase; US, ultrasound.
Table 3. Clinical protocols used in sonothrombolysis
Clot model Drug
Mode
MBs Freq. Output
PRF
(Hz)
DF
(%)
Time
(min)
Evaluation
method Main conclusion
Side
effects Ref.
US
alone
Drug
alone US + drug
Stroke patients
MCA occlusion
rt-PA
(.9 mg/kg)
Yes (TCD) Yes 2 MHz n/s n/s n/s 120 Measured complete
and partial
recanalization rate
50% (6/12) 0% sICH 81
33% (4/12)
MBs reached and permeated beyond
occlusions with no increase in sICH
suggesting
the feasibility of further studies
0% sICH
Stroke patients
MCA occlusion
Yes (TCD) 2 MHz n/s n/s n/s 60 Measured complete
recanalization rate
30% (4/12)
Sonothrombolysis using 2 probes and
bilateral monitoring is safe but not
more effective than standard
sonothrombolysis.
0% sICH 82
Stroke patients
MCA occlusion
Yes (TCCD) 2 MHz 415 mW/cm2
(ISPTA)
n/s n/s 30 Measured partial
recanalization rate
83% (5/6)
High rate of early partial recanalization
during continuous exposure to 2-MHz
US without rt-PA.
0% sICH 83
Stroke patients
MCA occlusion
rt-PA
(.9 mg/kg)
Yes 120 Measured complete
recanalization rate
24% (9/36) 5.5% sICH 84
Yes (TCD) 2 MHz n/s n/s n/s 120 41% (15/37) 2.7% sICH
Yes (TCD) Yes 2 MHz n/s n/s n/s 120 55% (21/38)
MBs administration induces further
acceleration of US-enhanced
thrombolysis.
2.6% sICH
Stroke patients
MCA occlusion
rt-PA
(.9 mg/kg)
Yes (TCCD) 2 MHz 189 mW/cm2 n/s n/s 60 Measured complete
recanalization rate
53% (8/15) 7% sICH 85
Yes (TCCD) Yes 2 MHz 189 mW/cm2 n/s n/s 60 64% (7/11)
MBs enhanced TCCD monitored rt-PA
thrombolysis lead to a greater
immediate clinical improvement.
9% sICH
Stroke patients
MCA occlusion
rt-PA
(.9 mg/kg)
Yes 60 Measured complete
and partial
recanalization rate
21.4% (3/14—complete)
0% (0/14—partial)
7% sICH 8
Yes (TCCD) 2-4 MHz 179 mW/cm2 n/s n/s 60 27.3% (3/11—complete)
18.2% (2/11—artial)
Transcranial TCCD with rt-PA showed
a higher grade of recanalization
compared with rt-PA alone.
36% sICH
Stroke patients
MCA occlusion
rt-PA
(.9 mg/kg)
Yes 120 Measured complete
recanalization rate
30% (19/63) 5% sICH 9
Yes (TCD) 2 MHz 750 mW/cm2 n/s n/s 120 49% (31/63)
Continuous TCD augments rt-PA-
induced arterial recanalization.
5% sICH
Stroke patients
MCA occlusion
rt-PA
(.9 mg/kg)
Yes
(TCD)
2 MHz n/s n/s n/s 120 Measured complete
recanalization rate
36% (20/55)
Complete recanalization within 2 h
after rt-PA bolus is a feasible goal for
thrombolysis given with TCD
monitoring.
6% sICH 86
(continued on next page)
Table 3. (continued)
Clot model Drug
Mode
MBs Freq. Output
PRF
(Hz)
DF
(%)
Time
(min)
Evaluation
method Main conclusion
Side
effects Ref.
US
alone
Drug
alone US + drug
Stroke patients
MCA occlusion
rt-PA
(.9 mg/kg)
Yes 60 Measured complete
and partial
recanalization rate
11.1% (2/18—complete)
11.1% (2/18—partial)
5.6% sICH 10
Yes (TCCD) 1.8 MHz 179 mW/cm2 n/s n/s 60 15.8% (3/19—complete)
42.1% (8/19—partial)
Transcranial US in combination with
rt-PA accelerates recanalization in
MCA occlusion, compared with rt-PA
alone
15.8%sICH
Stroke patients
MCA occlusion
rt-PA
(.9 mg/kg)
Yes 90 Measured
recanalization rate
(both complete and
partial)
50% (6/12)
29% (4/14)
Low frequency US combined with rt-
PA showed an increased rate of sICH.
0% sICH 87
Yes 300 kHz 700 mW/cm2
(ISPTA)
100 5 90 36% sICH
Stroke patients
Proximal
intracranial
occlusion
rt-PA
(.9 mg/kg)
Yes 90 Measured complete
and partial
recanalization rate
33% (4/12—complete)
25% (3/12—partial)
0% sICH 88
Yes (TCD) Yes
(1.4 mL)
2 MHz n/s n/s 100 90 67% (8/12—complete)
17% (2/12—partial)
0% sICH
Yes (TCD) Yes
(2.8 mL)
2 MHz n/s n/s 100 90 45% (5/11—complete)
0% (0/11—partial)
MBs can be safely combined with
systemic rt-PA and US at a dose of
1.4 mL.
27% sICH
Stroke patients
MCA occlusion
rt-PA
(.9 mg/kg)
Yes (TCCD) 2-4 MHz 208 W/cm2
(ISPPA)
5 k .7 45 Measured complete
and partial
recanalization rate
97% (36/37—complete)
0% (0/37—partial)
2.7% sICH 89
Yes 45 67% (10/15—complete)
7% (1/15—partial)
6.6% sICH
Yes (TCCD) 2-4 MHz 208 W/cm2
(ISPPA)
5 k .7 45 80% (12/15—complete)
7% (1/15—partial)
Recanalization rate of continuous
TCCD monitoring of MCA occlusion
in combination with rt-PA was lower
compared with that of TCCD
monitoring alone.
6.6% sICH
Stroke patients
MCA occlusion
Catheter type
rt-PA
(60 mg IV
+ 22 mg
IA
infusion)
Yes Yes 1.7 MHz n/s n/s n/s 120
120
Measured
recanalization rate
(both complete and
partial)
56% (33/59)
73% (24/33)
EKOS micro-infusion catheter is a
reasonable and easy-to-use tool for re-
opening occluded intracranial arteries.
Additionally, the delivery of intra-
arterial rt-PA or other thrombolytic
drugs via a standard micro-catheter
remains an excellent option.
6.6% sICH
9.9% sICH
90
DF, duty factor; Freq., frequency; IA, intrarterial; IV, intravenous; MBs, microbubbles; MCA, middle cerebral artery; n/s, not specified; PRF, pulse repetition frequency; Ref., references; rt-PA,
recombinant tissue plasminogen activator; sICH; symptomatic intracranial hemorrhage; TCD, transcranial Doppler; TCCD, transcranial color-coded duplex; US, ultrasound.
The treatment time used varied from 30 minutes to 10
minutes. In the animal and human studies, there was no
need to specify the temperature. It is assumed that the
specie of interest had the physiological temperature. In
the human trials the modality used was the synergy of
US and thrombolytic drugs. In some cases,8,84,85,88 the
synergy with MBs was used.
Discussion
The current study compiled various aspects associ-
ated with the protocols examined (in vitro, in vivo, and
clinical) that are used in sonothrombolysis. The review
protocols are summarized in tables providing all neces-
sary data in terms of clot model, treatment mode, sonication
parameters, evaluation method, sonothrombolysis effi-
cacy, and side effects. In addition, the main conclusions
derived from each study are presented as well. This study
could be useful for future researchers in this area because
they can easily find the US parameters used during
sonothrombolysis. Additionally, they can make compar-
ison among the various protocols used and the animal
models used.
Although the mechanisms behind sonothrombolysis are
not very clear, it is evidenced that exposure to US in-
creases the uptake and depth of penetration of
thrombolytics into clots,19 causes additional binding sites
due to reversible disaggregation of fibrin fibers,18 and in-
creases the binding of thrombolytic agents to fibrin.17
The influence of temperature on clot lysis was only in-
vestigated in vitro. In most of the experimental studies,
the temperature during sonication was kept constant at
37°C, which sufficiently explains that clot lysis occurred
through nonthermal mechanisms. In a few in vitro studies,
the temperature at the target was not specified. Temper-
ature played an important role on clot lysis because
sonothrombolysis efficacy decreased at temperatures below
the body baseline temperature of 37°C.34 Therefore, it will
be useful in the future, for all the in vitro studies to be
conducted at 37°C.
In the animal studies the most common clot models
used were the rabbit model (e.g., References 66-74). In
the popular rabbit model, the most commonly used artery
was the femoral, followed by the MCA and the carotid.
The femoral model is used mostly because this artery is
easily accessible. The MCA is widely used because of its
relevance to brain stroke.
Different thrombolytic drugs such as UK, streptoki-
nase, alteplase (rt-PA), and tenecteplase tissue plasminogen
activator (TNK-tPA) in various concentrations have been
investigated. Studies had shown that the synergy of US
and any of these drugs could accelerate the thrombolytic
activity of any thrombolytic used and that the extent of
sonothrombolysis depended on the drug’s concentration.25,59
The most common thrombolytic drug used by the re-
searchers was rt-PA, because it is the only thrombolytic
treatment approved for acute ischemic stroke. Although
rt-PA was administered in various concentrations between
.1 and 300 µg/mL, the majority of the above-mentioned
studies were conducted using 3.15 µg/mL rt-PA, which
is the average concentration of the drug detected in human
blood.
The current review shows that the thrombolytic effi-
cacy of drug alone is better than that of US alone.23,30,35
Therefore, we assume that US energy as a stand-alone
method for clot lysis is not effective and should be applied
in synergy with thrombolytic drugs to enhance
sonothrombolysis. However, a few studies43,44,46 demon-
strated that using US alone (in the absence of thrombolytic
drug), could achieve almost complete clot lysis within
seconds. Taking into consideration the very high level of
acoustic power used in their studies as well as the tem-
perature elevation at the target that was not specified in
their results, we suspect that most likely the protocols
applied were under the influence of thermal mecha-
nisms of sonothrombolysis. This suspicion was supported
by the results of many other researchers,23,30,35 who ex-
hibited reduced thrombolytic efficacy using US alone,
although prolonged exposure times were used in their
studies.
Some other studies focused their research on the effect
of traveling versus standing acoustic waves on clot lysis,
demonstrating that traveling acoustic waves enhanced
sonothrombolysis significantly more than standing waves
did.11,29 It is evident that researchers in this area should
report whether standing waves are eliminated irrespec-
tive of the model used (in vitro, animal, or human).
It is well known that US frequency, as well as acous-
tic intensity, exerts a major effect on clot lysis. US
frequencies ranged from 20 kHz to 5.0 MHz and intensities
(either low or high) were employed for sonothrombolysis
studies. A number of studies indicated that lower US fre-
quencies (in the kilohertz range), are more efficient in
sonothrombolysis over higher frequencies (in the MHz
range) because they exhibited improved tissue penetra-
tion and greater acceleration in fibrinolysis.16,37,38 Considering
that some other studies showed that sonothrombolysis
efficacy increases as the level of acoustic intensity
increases,24,26,28 it is reasonable to come to the conclu-
sion that the thrombolytic efficacy of US waves is directly
dependent on acoustic intensity and inversely depen-
dent on frequency.
There was enough evidence from in vitro,50 animal,75
and clinical84 studies indicating that the administration
of MBs further enhanced the effect of US on enzymatic
thrombolysis induced by thrombolytic agents. The find-
ings of this review demonstrate that the boosting effect
of MBs in clot dissolution correlated with the presence
of cavitation mechanisms and most specifically with stable
cavitation, which appeared to play a more important role
in MB-mediated sonothrombolysis.48,51,54 However, a study
performed by Molina et al88 showed that there is a safe
limit on the administered dose of MBs, which should not
be exceeded because it is associated with an increased
risk of symptomatic intracranial hemorrhage (sICH) rate.
Therefore, it is recommended that MBs should be
administered in combination with rt-PA at low doses
(1.4 mL) to enhance sonothrombolysis and avoid unnec-
essary adverse health effects, such as sICH.
Animal studies, as well as clinical trials, have shown
that the most common side effect of sonothrombolysis
was sICH. Apart from the use of high dose of MBs, the
application of low-frequency US might have increased
the rate of sICH. The TRanscranial low-frequency
sonothrombolysis in Brain Ischemia (TRUMBI) clinical
trial,87 which was designed to treat stroke patients with
transcranial 300 kHz US plus rt-PA, was ended prema-
turely due to a significant increase in sICH rate. Since
then, low-frequency US has not been available for ther-
apeutic purposes in clinical trials. Additionally, our
investigation showed that the risk of sICH rate in-
creases with the concentration of thrombolytic drug63 and
the level of acoustic intensity.64,65
The effect of time is very critical on sonothrombolysis
efficacy because early recanalization is the key to ther-
apeutic success in the treatment of vascular thrombosis.
In this review, the exposure times reported in the in vitro
studies varied from .5 to 240 minutes. In the animal studies,
the treatment times reported ranged from .5 to 120 minutes,
whereas in the clinical trials, the continuous monitoring
of the patients was between 30 and 120 minutes. Several
studies1,33 showed that most of the clot mass was removed
within the first 60 minutes of treatment and beyond that
time the efficacy of thrombolytic treatment was de-
creased significantly. This phenomenon was possibly caused
by the concentration of the thrombolytic drug in the blood
after 60 minutes of treatment, which decreased dramat-
ically, leading to a significant reduction on enzymatic
fibrinolysis rate. Therefore, at least for in vitro or animal
studies, 60 minutes of treatment must be a sufficient
exposure time and should not be exceeded. The long treat-
ment time required to remove clots using sonothrombolysis
prohibits the use of this method for large occluded volumes.
Perhaps, the physicians will attempt to treat critical clots,
thus saving as much tissue as possible, given the long
treatment time needed. To treat larger occluded volumes,
a multi-element transducer technology is needed.
It is evident that the long treatment time needed (30-
90 minutes) to dissolve a small amount of clot imposes
a limitation of the wider use of sonothrombolysis. Because
the time allowed to deliver the therapy is between 3 and
6 hours, the long treatment time needed limits the wide
use of sonothrombolysis.
The analysis of the protocols used in the studies evalu-
ated revealed that there is a lack of standardization in
the recording of the ultrasonic dose. Some studies re-
ported acoustic pressure, some other studies reported
power, and some reported intensity.
The most common protocol used in clinical trials so
far for the treatment of patients with acute ischemic stroke
due to occlusion of the MCA was the continuous
monitoring of the patients with high-frequency (2 MHz)
low-intensity (<750 mW/cm2) diagnostic transcranial US
in combination with rt-PA.83,85 Using this protocol, higher
recanalization rates were exhibited compared with those
with rt-PA alone.
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